MX2018013622A - Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada. - Google Patents
Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.Info
- Publication number
- MX2018013622A MX2018013622A MX2018013622A MX2018013622A MX2018013622A MX 2018013622 A MX2018013622 A MX 2018013622A MX 2018013622 A MX2018013622 A MX 2018013622A MX 2018013622 A MX2018013622 A MX 2018013622A MX 2018013622 A MX2018013622 A MX 2018013622A
- Authority
- MX
- Mexico
- Prior art keywords
- cell death
- programmed cell
- defects
- diseases associated
- treatments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a miméticos de péptidos cíclicos del dominio que se une a la terminal C del TSP-1; la presente invención también se refiere al uso de estos péptidos cíclicos como agonistas del CD47 y su habilidad para disparar muerte celular programada (PCD); la presente invención se refiere además a una composición farmacéutica para usarse en el tratamiento de enfermedades asociadas con defectos en la PCD, tales como cánceres y trastornos de inmunodeficiencia (incluyendo inflamación crónica) y que comprende por lo menos un péptido cíclico de conformidad con la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305543.7A EP3243522A1 (en) | 2016-05-10 | 2016-05-10 | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| PCT/EP2017/061233 WO2017194634A1 (en) | 2016-05-10 | 2017-05-10 | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013622A true MX2018013622A (es) | 2019-08-01 |
Family
ID=56014941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013622A MX2018013622A (es) | 2016-05-10 | 2017-05-10 | Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11306124B2 (es) |
| EP (2) | EP3243522A1 (es) |
| JP (1) | JP7166933B2 (es) |
| KR (1) | KR102566709B1 (es) |
| CN (1) | CN109328067B (es) |
| AU (1) | AU2017263038B2 (es) |
| CA (1) | CA3023670C (es) |
| IL (1) | IL262805B2 (es) |
| MX (1) | MX2018013622A (es) |
| WO (1) | WO2017194634A1 (es) |
| ZA (1) | ZA201808186B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020007383A (es) | 2018-01-12 | 2020-10-12 | Aurigene Discovery Tech Ltd | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47. |
| EP3650036A1 (en) | 2018-11-06 | 2020-05-13 | Sorbonne Universite | Synthetic peptides inducing immunogenic cell death |
| US11311517B2 (en) | 2018-11-08 | 2022-04-26 | Aurigene Discovery Technologies Limited | Combination of small molecule CD-47 inhibitors with other anti-cancer agents |
| CN120775062A (zh) | 2019-07-16 | 2025-10-14 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| MY209360A (en) | 2019-10-31 | 2025-07-03 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| WO2021102322A1 (en) * | 2019-11-21 | 2021-05-27 | Unnatural Products Inc. | Cell-permeable cyclic peptides and uses thereof |
| PL4081305T3 (pl) | 2019-12-24 | 2025-02-10 | Carna Biosciences, Inc. | Związki modulujące kinazę diacyloglicerolową |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| EP4127139A1 (en) | 2020-03-27 | 2023-02-08 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2022003568A1 (en) | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CN112480231B (zh) * | 2020-12-14 | 2022-05-24 | 上海交通大学 | 一种生物活性肽kqslppglavkdlk及其制备方法和应用 |
| JP2024510989A (ja) | 2021-03-12 | 2024-03-12 | メンドゥス・ベスローテン・フェンノートシャップ | ワクチン接種方法及びｃｄ４７遮断薬の使用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TWI857377B (zh) | 2021-10-28 | 2024-10-01 | 美商基利科學股份有限公司 | 嗒-3(2h)-酮衍生物 |
| MX2024005066A (es) | 2021-10-29 | 2024-05-24 | Gilead Sciences Inc | Compuestos de cd73. |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| PE20242225A1 (es) | 2022-03-17 | 2024-11-19 | Gilead Sciences Inc | Degradadores de dedos de zinc de la familia ikaros y usos de estos |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| AU2023256670A1 (en) | 2022-04-21 | 2024-10-17 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | CD73 COMPOUNDS |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198949B2 (en) | 2012-06-06 | 2015-12-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of cancer |
-
2016
- 2016-05-10 EP EP16305543.7A patent/EP3243522A1/en not_active Withdrawn
-
2017
- 2017-05-10 IL IL262805A patent/IL262805B2/en unknown
- 2017-05-10 WO PCT/EP2017/061233 patent/WO2017194634A1/en not_active Ceased
- 2017-05-10 EP EP17725898.5A patent/EP3454880B1/en active Active
- 2017-05-10 CN CN201780034649.7A patent/CN109328067B/zh active Active
- 2017-05-10 CA CA3023670A patent/CA3023670C/en active Active
- 2017-05-10 KR KR1020187035361A patent/KR102566709B1/ko active Active
- 2017-05-10 AU AU2017263038A patent/AU2017263038B2/en active Active
- 2017-05-10 JP JP2018559280A patent/JP7166933B2/ja active Active
- 2017-05-10 MX MX2018013622A patent/MX2018013622A/es unknown
- 2017-05-10 US US16/099,997 patent/US11306124B2/en active Active
-
2018
- 2018-12-04 ZA ZA2018/08186A patent/ZA201808186B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7166933B2 (ja) | 2022-11-08 |
| EP3454880A1 (en) | 2019-03-20 |
| EP3243522A1 (en) | 2017-11-15 |
| US11306124B2 (en) | 2022-04-19 |
| JP2019518737A (ja) | 2019-07-04 |
| CA3023670C (en) | 2025-06-17 |
| IL262805B2 (en) | 2023-12-01 |
| IL262805B1 (en) | 2023-08-01 |
| EP3454880B1 (en) | 2022-01-26 |
| CN109328067B (zh) | 2023-06-16 |
| AU2017263038A1 (en) | 2018-12-20 |
| CA3023670A1 (en) | 2017-11-16 |
| US20190135865A1 (en) | 2019-05-09 |
| CN109328067A (zh) | 2019-02-12 |
| AU2017263038B2 (en) | 2021-10-21 |
| ZA201808186B (en) | 2022-04-28 |
| KR20190016026A (ko) | 2019-02-15 |
| KR102566709B1 (ko) | 2023-08-11 |
| IL262805A (en) | 2018-12-31 |
| WO2017194634A1 (en) | 2017-11-16 |
| BR112018072915A2 (pt) | 2019-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013622A (es) | Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada. | |
| CL2018003438A1 (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos. | |
| MX2021013327A (es) | Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a. | |
| CO2019009234A2 (es) | Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas | |
| CL2019000681A1 (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| MX2019003298A (es) | Proteinas de union recombinantes y sus usos. | |
| MX2015003229A (es) | Composiciones que comprenden mezclas de alcanos semifluorados. | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| MX2019002998A (es) | Celulas t con resistencia incrementada a la inmunosupresion. | |
| CL2019003430A1 (es) | Tratamiento conjunto antineoplásico. | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| CL2017003152A1 (es) | Composiciones de hidroxipropil beta-ciclodextrina y métodos | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| PE20181088A1 (es) | Mecanismo de resistencia a inhibidores de bromodominio bet | |
| MX377089B (es) | Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral. | |
| MX2019005874A (es) | Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg. | |
| EP3647321A4 (en) | PEPTIDE FOR TOLL-TYPE RECEPTOR (TLR) INHIBITION AND PHARMACEUTICAL COMPOSITION CONSISTING OF IT | |
| PE20180691A1 (es) | Variantes de il-37 | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| CO2017011583A2 (es) | Polipéptidos dirigidos a la fusión de vih | |
| AR120914A1 (es) | PROTEÍNAS DE UNIÓN A TGF-b-RII | |
| BR112019011461A2 (pt) | terapia celular à base de nk melhorada |